Global Health Ventures Receives the First Shipment of Its Commercially Manufactured Male Enhancement Drug "X-Excite"

VANCOUVER, BRITISH COLUMBIA, Nov 09 (MARKET WIRE) --
Global Health Ventures Inc. (OTCBB: GHLV), or the "Company" a Specialty
Pharma is pleased to announce today that it has completed the prototype
manufacturing of the drug "X-Excite" Global's male enhancement drug. The
manufacturing of the product was carried out under contract with Vida
Pharma of Montreal, Canada. Vida Pharma specialized in the designing of
the new tablet size, taste, and hardness. The Company has manufactured
over 4000 pills from several different incipient and coatings that are
all safe for human consumption. These various batches will be tested at
the University of British Columbia, Canada for independent evaluation in
regards to drugs adsorption, taste, color and hardness. If the samples
meet our end goals then the drug will be ready for mass production under
the proprietary formula for testing in humans and finally applying for
regulatory approval.

The Company plans to meet the regulatory bodies in the United States,
Canada and Europe to assess the time and length of the human clinical
trials in the near future. The X-Excite drug is the Company's lead
prescription drug. The Company is hoping to manufacture it so it can be
qualified under the OTC (over the counter for pharmaceuticals) Market. If
approvals are attained we believe that the product will generate a very
lucrative revenue stream for Global Health.

Our lead life-style pharmaceutical product, (X-Excite), is a male sexual
enhancement drug. X-Excite is a new formulation of an existing sexual
enhancement drug, which is designed to rapidly enter the blood system,
maximizing its efficacy and performance. The drug is developed to work
sublingually, thus having a more rapid mode of action, and bypassing all
the inconveniences and many side effects associated with other
application routs. Life style products, such as Viagra(TM), Cialis(TM)
and Levitra(TM), etc are highly lucrative, (nearly $5 billion) products
for pharmaceutical companies. This lucrative market will continue to grow
for the foreseeable future. The arrival of our new drug (X-Excite) with
its fewer side effects and the rapid mode of action meets and will exceed
the markets needs. The Company believes it will be able to take a lion's
share of the market thus generating significant revenue for the Company.

"We are pleased that we have completed the research on this product and
the manufacturing seems not to be a difficult or expensive process. With
the recent successful fund raising, the Company should be able to push
the approval of this product through regulatory doors". Said Dr. Salari,
President and CEO.

About Global Health Ventures, Inc.

Global Health Ventures, Inc. (the "Company") is a specialty pharma with
focus on the Over-The-Counter drug market. The Company has a new
proprietary platform technology that delivers many approved drugs via the
sublingual (under the tongue) route. This unique method delivers low dose
drugs directly to the blood stream, bypassing all the side effects of
digestive and liver system breakdowns, while maintaining product
efficacy. The Company currently has five products in late stage
development and several more underway.

Safe Harbor Statement

This press release includes forward-looking statements that involve a
number of risks and uncertainties, including the success of the products
in commercializing and developing. Further, the risks involve the ability
of the Company to raise capital to fund its operations and the capital
requirements for the development and marketing of its products. Investors
are encouraged to review the risk factors listed or described from time
to time in the Company's filings (10K) with the Securities and Exchange
Commission.

Contacts:
Global Health Ventures Inc.
Dr. Hassan Salari, Ph.D.
President & CEO
Toll free: 1-877-448-4620 or Tel: + 604-324-4844
hsalari@globalhealth3000.com
www.globalhealth3000.com

Copyright 2009, Market Wire, All rights reserved.

-0-